Compass Pathways

#Neuropsychiatry #Treatment-resistant Depression #Psychedelic Medicine

Compass Pathways is a public biotechnology company developing investigational psilocybin-based therapies and related care models for treatment-resistant depression and other mental-health conditions.

Company Info

Sector:Neuropsychiatry and Psychedelic Medicine

Headquarters:London, United Kingdom

Founded:2016

Website:compasspathways.com/

Clinical Development Pipeline

COMP360

Target: Psilocybin therapy

Treatment-resistant depression

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Compass’ psilocybin depression drug works for the long haul ↗

BioSpace reports: Compass’ psilocybin depression drug works for the long haul.

Leadership Team

Kabir Nath

Chief Executive Officer

Careers & Job Openings

See all open roles

Multiple Departments

London, United Kingdom

Apply Now →